|
The Board of Henderson Morley plc (“Henderson Morley” or “the Company”), notes the movement in the Company’s share price this morning, and press comment today that the Company has “agreed a multi-million pound deal with a major pharmaceuticals group”.
The Company is able to confirm that it is in an advanced stage of contractual negotiations with a potential partner to licence certain applications of its Ionic Contra Viral Therapy (“ICVT”) technology, however no agreement has as yet been formally agreed. The Company is able to confirm that, if an agreement is signed, it is likely to involve the Company receiving a series of milestone, development and commercialisation payments during the period of product development and, ultimately, royalty payments based on sales of the products derived from using the ICVT technology.
The Company will make a further announcement as and when appropriate. |
